On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc. notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | +1.22% | -1.89% | -24.55% |
May. 15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.55% | 36.55M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Marker Therapeutics, Inc. Announces Mythili Koneru, to Resign as Chief Medical Officer, Effective as of April 9, 2023